Platelet Transfusion During Neonatal Open Heart Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 11, 2017

Primary Completion Date

October 1, 2018

Study Completion Date

November 1, 2018

Conditions
Cardiac DiseaseCardiac SurgeryCardiopulmonary BypassPlatelet TransfusionArrythmia, CardiacMortality
Interventions
BIOLOGICAL

Platelet Transfusion

"Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion.~1. Initial transfusion to occur proximal to the hemofilter on the MUF circuit for as long as MUF lasts~2. Subsequent platelet transfusion continued till completion via central venous access to the patient"

BIOLOGICAL

FFP and Cryoprecipitate

"1. 1 unit of cryoprecipitate administered during MUF and or after MUF as needed~2. FFP transfusion 10ml/kg during MUF and or after MUF as needed"

BIOLOGICAL

PRBC and cell saver Transfusion

1\. Transfuse for target Hematocrit \> 40 in neonates with SV physiology; Transfuse for Hematocrit\> 33 for 2-Ventricle physiology

BIOLOGICAL

Factor Concentrate (Bebulin)

1\. Based on clinical bleeding and achievement of hemostasis

Trial Locations (1)

77030

Memorial Hermann Hospital, Houston

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER

NCT03045068 - Platelet Transfusion During Neonatal Open Heart Surgery | Biotech Hunter | Biotech Hunter